Deutsche Bank set a €87.00 ($97.75) target price on Bayer (FRA:BAYN) in a research note issued to investors on Friday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Several other research analysts have also weighed in on the company. DZ Bank reiterated a buy rating on shares of Bayer in a report on Tuesday, July 7th. Baader Bank set a €105.00 ($117.98) target price on Bayer and gave the stock a buy rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. set a €77.00 ($86.52) target price on Bayer and gave the stock a neutral rating in a report on Thursday, July 9th. Independent Research set a €66.00 ($74.16) price target on Bayer and gave the company a neutral rating in a research note on Friday. Finally, Barclays set a €80.00 ($89.89) price target on Bayer and gave the company a buy rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of €84.41 ($94.84).

BAYN stock opened at €64.50 ($72.47) on Friday. The business’s 50-day moving average price is €65.18 and its two-hundred day moving average price is €65.01. Bayer has a 1-year low of €91.58 ($102.90) and a 1-year high of €123.82 ($139.12).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Further Reading: FinTech

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.